Drug Target Review2025-09-23T09:00:00
A new oral immunotherapy could change how peanut allergy is treated, targeting the gut to retrain the immune system and reduce the risk of life-threatening reactions. INP20’s nanoparticle technology promises a safer, more precise approach that could replace lifelong avoidance with lasting tolerance.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-08-20T08:43:00Z
Author Dr Daniel Tillett
2026-09-23T15:00:00
Sponsored by BioIVT
2026-06-04T07:05:00
Author Graham Craig
2025-04-22T14:58:00
Sponsored by Takara Bio USA
2024-03-08T10:00:25
Sponsored by Molecular Devices
2023-01-20T14:24:55
Sponsored by Leica Microsystems
2026-08-10T08:58:00
Author Abhishek Jha
Site powered by Webvision Cloud